Large Molecule Bioanalytical Testing Services Market

Bioanalytical research swells globally, upscaling revenue of Large Molecule Bioanalytical Testing Service Providers: Opportunities ahead

Large Molecule Bioanalytical Testing Services Market by Phase, Type, Test Type, Therapeutic Area & Region | Forecast 2023 to 2033

Request Sample Talk to Analyst

Large Molecule Bioanalytical Testing Services Market Outlook (2023 to 2033)

Newly-released Large Molecule Bioanalytical Testing Service industry analysis report by Future Market Insights reveals that global sales of Large Molecule Bioanalytical Testing Market in 2022 were held at US$ 1.3 Billion. With a CAGR of 12.1% from 2023 to 2033, the market is projected to reach US$ 4.7 Billion by 2033. Clinical Phase is expected to generate significant revenue and is projected to grow at a CAGR of 10.9% from 2023 to 2033.

Attribute	Details
Global Market Size (2023)	US$ 1.5 Billion
Global Market Size (2033)	US$ 4.7 Billion
Global Market Size CAGR (2023 to 2033)	12.1%
U.S. Market Size CAGR (2023 to 2033)	12.3%
Key Companies Profiled	Covance IQVIA Syneos Health SGS SA Toxikon Intertek Group plc Pace Analytical Services LLC ICON Plc Charles River Laboratories Thermo Fisher Scientific

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Revenue of Large Molecule Bioanalytical Testing Service from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per the Large Molecule Bioanalytical Testing Service industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, market value of the Large Molecule Bioanalytical Testing Service industry increased at around 11.9% CAGR, wherein, countries such as the USA, China, Japan, United kingdom and South Korea held significant share in the global market.

The increase in demand for forward-looking and high-grade large molecule bioanalytical testing services is expected to propel the market forward. Reduced time to market, increased regulatory observation, and a high risk of product failure are a few of the factors driving the demand for large molecule bioanalytical testing services. Owing to this, the Large Molecule Bioanalytical Testing Service market is projected to grow at a CAGR of 12.1% over the coming 10 years.

Because of rising healthcare expenditures, there is a greater need for high-quality care. The demand for analytical testing is developing in response to new pharmaceutical product advancements. Due to increased competition in the healthcare business and rising pricing concerns, many companies are turning to outsourcing services for analytical testing.

The demand for analytical testing has increased as research and development activities for new medication development, combination products, and other complex medicines have increased.

What are the key drivers for Large Molecule Bioanalytical Testing Service revenue?

With the prevalence of HIV, infectious illnesses, and other disorders, the demand for bioanalytical testing services has shot up in the recent past. Furthermore, enhanced government actions to control the spread of infectious diseases like Corona and the Ebola virus are expected to assist the business. As a result, the market is expected to grow throughout the assessment period.

Throughout the projection period, increased research activities and the presence of a vast pipeline of peptides, biologics, and amino acid-based compounds are expected to move the market ahead. Bioanalysis of large molecules also involves the utilization of highly skilled professionals as well as analytical gear and infrastructure.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Region-wise Analysis

Which Region is projected to Offer the Significant Opportunity for Large Molecule Bioanalytical Testing Service?

With a CAGR of 12.3% during the projected period, Large Molecule Bioanalytical Testing Service revenue is expected to grow at a significant pace in North America. Because of the rising frequency of numerous chronic diseases and the growing use of large-molecule medicines as an alternative to small molecules, the United States has the largest market share.

According to the International Diabetic Federation Report 2019, the United States has a diabetic population of 49 million geriatrics, which has resulted in an increase in demand for bioanalysis of new peptide therapies such as glucagon-like peptide 1. As a result, the market is likely to grow throughout the forecast period. Furthermore, the presence of large firms in the region aided market expansion.

Country-wise Analysis

USA Large Molecule Bioanalytical Testing Service Market Analysis

As one of the main production hubs for highly dependable, complicated, and high-end pharmaceuticals, the USA accounted for a significant share of the global market in 2022. The market is likely to be driven by rapid technology improvements and increasing demand for bioanalytical testing services. Furthermore, because of the country's developing healthcare business, biopharmaceutical companies are focusing on the USA market.

United kingdom Large Molecule Bioanalytical Testing Service Market Analysis

The market in the United kingdom is expected to reach a valuation of US$ 180.6 Million by 2033. Growing with a CAGR of 12.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 127 Million.

Japan Large Molecule Bioanalytical Testing Service Market Analysis

In Japan, the market is expected to grow at a CAGR of 10.8% from 2023 to 2033, reaching around US$ 161 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 104 Million during the forecast period.

South Korea Gastro-retentive Drug Delivery Systems Market Analysis

The market in South Korea is expected to reach a valuation of around US$ 123 Million by 2033, growing at a CAGR of 12.6% from 2023 to 2033. The market in the country is expected to witness an absolute dollar opportunity of around US$ 85 Million.

Category-wise Insights

Which Phase of Large Molecule Bioanalytical Testing Services will Generate Significant Revenue in the Market in the Forthcoming years?

The clinical segment is expected to grow at a CAGR of 10.9%. Based on the study phase, the market is segmented into preclinical and clinical. The rising frequency of chronic diseases and the growing demand for clinical trials in developing countries are likely to propel the segment forward.

Which Large Molecule Bioanalytical Testing Services Type will be Most Preferred?

The market through Antidrug Antibodies (ADA) is expected to grow at a CAGR of 11.8% during the forecast period. Large-molecule drug development is aided by ADA assays. Antibodies against large molecule medications, such as antibody or protein therapies, are produced by the immune system. As a result, ADAs can be detected using ADA tests. Patients who create an antibody response will have a variety of reactions, ranging from life-threatening to no clinical implications. This can lead to anaphylactic shock, allergic responses, or autoimmunity, among other things.

Pharmacokinetic expert services are carried out in accordance with GCP specifications as well as international regulatory rules. Moreover, clinical trials for biologics and biosimilars include a trial to measure the concentration of this drug in healthy volunteers.

The ELISA or MSD platform is used to offer this service. A commonly utilized immunoassay for the detection of significant in vitro pharmacokinetic research is ELISA. In line with the chemical construction and principle of operation of drug substances, antibody sensitivity in pharmacokinetic immunoanalysis should always be fixed.

Competitive Analysis

The key players operating in the Large Molecule Bioanalytical Testing Services Market include Covance, IQVIA, Syneos Health, SGS SA, Toxikon, Intertek Group plc, Pace Analytical Services LLC, ICON Plc, Charles River Laboratories, and Thermo Fisher Scientific.

Few of the recent developments of key Large Molecule Bioanalytical Testing Service providers are as follows:

In November 2021, Labcorp announced the introduction of a new bioanalytical lab facility in Singapore. This laboratory is an expansion of its central laboratory services and will enable to the expansion of the capabilities of the biomedical ecosystem in Singapore.
In February 2021, Nexelis acquired GSK’s Marburg, Germany-based vaccines clinical bioanalytical laboratory for expanding its bioanalytical capabilities.

Similarly, recent developments related to companies in the Large Molecule Bioanalytical Testing Services have been tracked by the team at Future Market Insights, which are available in the full report.

Market Segments Covered in Large Molecule Bioanalytical Testing Service Industry Analysis

By Phase:

Preclinical
With Antibody
Without Antibody
Clinical

By Type:

Pharmacokinetics
ADA
Others

By Test Type:

ADME
PK
PD
Bioavailability
Bioequivalence
Other Tests

By Therapeutic Area:

Oncology
Infectious Diseases
Cardiology
Neurology
Others

By Region:

North America
Latin America
Europe
APAC
MEA

Frequently Asked Questions

How much is the current worth of the Large Molecule Bioanalytical Testing Service market?

The market is worth more than US$ 1.5 Billion at present.

What is the sales forecast for Large Molecule Bioanalytical Testing Service?

The market value is projected to increase at a CAGR of around 12.1% from 2023 to 2033.

What was the last 5 year’s market CAGR?

The market value increased at a CAGR of around 11.9% from 2018 to 2022.

Who are the key players in the Large Molecule Bioanalytical Testing Service market?

The key players in Large Molecule Bioanalytical Testing Service market are Covance, IQVIA, Syneos Health, SGS SA, Toxikon, Intertek Group plc, Pace Analytical Services LLC, ICON Plc, Charles River Laboratories, and Thermo Fisher Scientific.

Which are the top 5 countries driving demand for Large Molecule Bioanalytical Testing Services?

Top 5 countries driving demand for Large Molecule Bioanalytical Testing Services are the USA, China, Japan, the United kingdom and South Korea.

What is the outlook for the market in USA?

USA will account for over 36% of global Large Molecule Bioanalytical Testing Service demand in 2033 with a CAGR of 12.3%

At what percentage is sales of Large Molecule Bioanalytical Testing Service going to register growth from 2023 to 2033?

The market for Large Molecule Bioanalytical Testing Services is projected to expand at a CAGR of around 12.1% during 2023 to 2033 with a global market size of US$ 4.7 Billion.

What do statistics for South Korea and Japan reveal?

While the market in South Korea is expected to grow at nearly 12.6%, the market in Japan is projected to register a CAGR of nearly 10.8% during 2023 to 2033.

Table of Content

1. Executive Summary | Large Molecule Bioanalytical Testing Services Market

1.1. Global Market Outlook

1.2. Summary of Statistics

1.3. Key Market Characteristics & Attributes

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage

2.2. Market Definition

3. Market Risks and Trends Assessment

3.1. Risk Assessment

3.1.1. COVID-19 Crisis and Impact on Large Molecule Bioanalytical Testing Services

3.1.2. COVID-19 Impact Benchmark with Previous Crisis

3.1.3. Impact on Market Value (US$ Million)

3.1.4. Assessment by Key Countries

3.1.5. Assessment by Key Market Segments

3.1.6. Action Points and Recommendation for Suppliers

3.2. Key Trends Impacting the Market

3.3. Formulation and Product Development Trends

4. Market Background

4.1. Large Molecule Bioanalytical Testing Services Market, by Key Countries

4.2. Opportunity Assessment (US$ Million)

4.2.1. Total Available Market

4.2.2. Serviceable Addressable Market

4.2.3. Serviceable Obtainable Market

4.3. Market Scenario Forecast

4.3.1. Demand in optimistic Scenario

4.3.2. Demand in Likely Scenario

4.3.3. Demand in Conservative Scenario

4.4. Investment Feasibility Analysis

4.4.1. Investment in Established Markets

4.4.1.1. In Short Term

4.4.1.2. In Long Term

4.4.2. Investment in Emerging Markets

4.4.2.1. In Short Term

4.4.2.2. In Long Term

4.5. Forecast Factors - Relevance & Impact

4.5.1. Top Companies Historical Growth

4.5.2. Growth in Automation, By Country

4.5.3. Large Molecule Bioanalytical Testing Services Adoption Rate, By Country

4.6. Market Dynamics

4.6.1. Market Driving Factors and Impact Assessment

4.6.2. Prominent Market Challenges and Impact Assessment

4.6.3. Opportunities

4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

5.2. Banking on with Segments High Incremental Opportunity

5.3. Peer Benchmarking

6. Global Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032

6.1. Historical Market Analysis, 2015 to 2021

6.2. Current and Future Market Projections, 2022 to 2032

6.3. Y-o-Y Growth Trend Analysis

7. Global Value Analysis 2015 to 2021 and Forecast, 2022 to 2032

7.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021

7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Phase

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Million) Analysis By Phase, 2015 to 2021

8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Phase, 2022 to 2032

8.3.1. Preclinical

8.3.1.1. With Antibody

8.3.1.2. Without Antibody

8.3.2. Clinical

8.4. Market Attractiveness Analysis By Phase

9. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Type

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Million) Analysis By Type, 2015 to 2021

9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Type, 2022 to 2032

9.3.1. Pharmacokinetics

9.3.2. ADA

9.3.3. Other Types

9.4. Market Attractiveness Analysis By Type

10. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Test Type

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Million) Analysis By Test Type, 2015 to 2021

10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032

10.3.1. ADME

10.3.2. PK

10.3.3. PD

10.3.4. Bioavailability

10.3.5. Bioequivalence

10.3.6. Other Test Types

10.4. Market Attractiveness Analysis By Test Type

11. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Therapeutic Area

11.1. Introduction / Key Findings

11.2. Historical Market Size (US$ Million) Analysis By Therapeutic Area, 2015 to 2021

11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapeutic Area, 2022 to 2032

11.3.1. Oncology

11.3.2. Infectious Diseases

11.3.3. Cardiology

11.3.4. Neurology

11.3.5. Other End-users

11.4. Market Attractiveness Analysis By Therapeutic Area

12. Global Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region

12.1. Introduction

12.2. Historical Market Size (US$ Million) Analysis By Region, 2015 to 2021

12.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032

12.3.1. North America

12.3.2. Latin America

12.3.3. Europe

12.3.4. Asia Pacific

12.3.5. Middle East and Africa (MEA)

12.4. Market Attractiveness Analysis By Region

13. North America Analysis 2015 to 2021 and Forecast 2022 to 2032

13.1. Introduction

13.2. Pricing Analysis

13.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

13.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

13.4.1. By Country

13.4.1.1. USA

13.4.1.2. Canada

13.4.1.3. Rest of North America

13.4.2. By Phase

13.4.3. By Type

13.4.4. By Therapeutic Area

13.4.5. By Test Type

13.5. Market Attractiveness Analysis

13.5.1. By Country

13.5.2. By Phase

13.5.3. By Type

13.5.4. By Therapeutic Area

13.5.5. By Test Type

14. Latin America Analysis 2015 to 2021 and Forecast 2022 to 2032

14.1. Introduction

14.2. Pricing Analysis

14.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

14.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

14.4.1. By Country

14.4.1.1. Brazil

14.4.1.2. Mexico

14.4.1.3. Rest of Latin America

14.4.2. By Phase

14.4.3. By Type

14.4.4. By Therapeutic Area

14.4.5. By Test Type

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Phase

14.5.3. By Type

14.5.4. By Therapeutic Area

14.5.5. By Test Type

15. Europe Analysis 2015 to 2021 and Forecast 2022 to 2032

15.1. Introduction

15.2. Pricing Analysis

15.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

15.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

15.4.1. By Country

15.4.1.1. Germany

15.4.1.2. France

15.4.1.3. United kingdom

15.4.1.4. Italy

15.4.1.5. Benelux

15.4.1.6. Nordic Countries

15.4.1.7. Rest of Europe

15.4.2. By Phase

15.4.3. By Type

15.4.4. By Therapeutic Area

15.4.5. By Test Type

15.5. Market Attractiveness Analysis

15.5.1. By Country

15.5.2. By Phase

15.5.3. By Type

15.5.4. By Therapeutic Area

15.5.5. By Test Type

16. Asia Pacific Analysis 2015 to 2021 and Forecast 2022 to 2032

16.1. Introduction

16.2. Pricing Analysis

16.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

16.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

16.4.1. By Country

16.4.1.1. China

16.4.1.2. Japan

16.4.1.3. South Korea

16.4.1.4. Rest of Asia Pacific

16.4.2. By Phase

16.4.3. By Type

16.4.4. By Therapeutic Area

16.4.5. By Test Type

16.5. Market Attractiveness Analysis

16.5.1. By Country

16.5.2. By Phase

16.5.3. By Type

16.5.4. By Therapeutic Area

16.5.5. By Test Type

17. Middle East and Africa Analysis 2015 to 2021 and Forecast 2022 to 2032

17.1. Introduction

17.2. Pricing Analysis

17.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021

17.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032

17.4.1. By Country

17.4.1.1. GCC Countries

17.4.1.2. South Africa

17.4.1.3. Turkey

17.4.1.4. Rest of Middle East and Africa

17.4.2. By Phase

17.4.3. By Type

17.4.4. By Therapeutic Area

17.4.5. By Test Type

17.5. Market Attractiveness Analysis

17.5.1. By Country

17.5.2. By Phase

17.5.3. By Type

17.5.4. By Therapeutic Area

17.5.5. By Test Type

18. Key Countries Analysis 2015 to 2021 and Forecast 2022 to 2032

18.1. Introduction

18.1.1. Market Value Proportion Analysis, By Key Countries

18.1.2. Global Vs. Country Growth Comparison

18.2. US Analysis

18.2.1. Value Proportion Analysis by Market Taxonomy

18.2.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.2.2.1. By Phase

18.2.2.2. By Type

18.2.2.3. By Therapeutic Area

18.2.2.4. By Test Type

18.3. Canada Analysis

18.3.1. Value Proportion Analysis by Market Taxonomy

18.3.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.3.2.1. By Phase

18.3.2.2. By Type

18.3.2.3. By Therapeutic Area

18.3.2.4. By Test Type

18.4. Mexico Analysis

18.4.1. Value Proportion Analysis by Market Taxonomy

18.4.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.4.2.1. By Phase

18.4.2.2. By Type

18.4.2.3. By Therapeutic Area

18.4.2.4. By Test Type

18.5. Brazil Analysis

18.5.1. Value Proportion Analysis by Market Taxonomy

18.5.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.5.2.1. By Phase

18.5.2.2. By Type

18.5.2.3. By Therapeutic Area

18.5.2.4. By Test Type

18.6. Germany Analysis

18.6.1. Value Proportion Analysis by Market Taxonomy

18.6.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.6.2.1. By Phase

18.6.2.2. By Type

18.6.2.3. By Therapeutic Area

18.6.2.4. By Test Type

18.7. France Analysis

18.7.1. Value Proportion Analysis by Market Taxonomy

18.7.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.7.2.1. By Phase

18.7.2.2. By Type

18.7.2.3. By Therapeutic Area

18.7.2.4. By Test Type

18.8. Italy Analysis

18.8.1. Value Proportion Analysis by Market Taxonomy

18.8.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.8.2.1. By Phase

18.8.2.2. By Type

18.8.2.3. By Therapeutic Area

18.8.2.4. By Test Type

18.9. BENELUX Analysis

18.9.1. Value Proportion Analysis by Market Taxonomy

18.9.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.9.2.1. By Phase

18.9.2.2. By Type

18.9.2.3. By Therapeutic Area

18.9.2.4. By Test Type

18.10. UK Analysis

18.10.1. Value Proportion Analysis by Market Taxonomy

18.10.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.10.2.1. By Phase

18.10.2.2. By Type

18.10.2.3. By Therapeutic Area

18.10.2.4. By Test Type

18.11. Nordic Countries Analysis

18.11.1. Value Proportion Analysis by Market Taxonomy

18.11.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.11.2.1. By Phase

18.11.2.2. By Type

18.11.2.3. By Therapeutic Area

18.11.2.4. By Test Type

18.12. China Analysis

18.12.1. Value Proportion Analysis by Market Taxonomy

18.12.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.12.2.1. By Phase

18.12.2.2. By Type

18.12.2.3. By Therapeutic Area

18.12.2.4. By Test Type

18.13. Japan Analysis

18.13.1. Value Proportion Analysis by Market Taxonomy

18.13.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.13.2.1. By Phase

18.13.2.2. By Type

18.13.2.3. By Therapeutic Area

18.13.2.4. By Test Type

18.14. South Korea Analysis

18.14.1. Value Proportion Analysis by Market Taxonomy

18.14.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.14.2.1. By Phase

18.14.2.2. By Type

18.14.2.3. By Therapeutic Area

18.14.2.4. By Test Type

18.15. GCC Countries Analysis

18.15.1. Value Proportion Analysis by Market Taxonomy

18.15.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.15.2.1. By Phase

18.15.2.2. By Type

18.15.2.3. By Therapeutic Area

18.15.2.4. By Test Type

18.16. South Africa Analysis

18.16.1. Value Proportion Analysis by Market Taxonomy

18.16.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.16.2.1. By Phase

18.16.2.2. By Type

18.16.2.3. By Therapeutic Area

18.16.2.4. By Test Type

18.17. Turkey Analysis

18.17.1. Value Proportion Analysis by Market Taxonomy

18.17.2. Value Analysis and Forecast by Market Taxonomy, 2015 to 2032

18.17.2.1. By Phase

18.17.2.2. By Type

18.17.2.3. By Therapeutic Area

18.17.2.4. By Test Type

18.17.3. Competition Landscape and Player Concentration in the Country

19. Market Structure Analysis

19.1. Market Analysis by Tier of Companies

19.2. Market Concentration

19.3. Market Share Analysis of Top Players

19.4. Market Presence Analysis

19.4.1. By Regional footprint of Players

19.4.2. Product footprint by Players

20. Competition Analysis

20.1. Competition Dashboard

20.2. Competition Benchmarking

20.3. Competition Deep Dive

20.3.1. Covance, Inc.

20.3.2. IQVIA

20.3.3. Syneos Health

20.3.4. Charles River Laboratory International

20.3.5. ICON Plc

20.3.6. SGS SA

20.3.7. Toxikon

20.3.8. Intertek Group plc

20.3.9. Pace Analytical Services LLC

20.3.10. PPD, INC.

21. Assumptions and Acronyms Used

22. Research Methodology

List of Tables

Table 1: Global Value (US$ Million),By Phase, 2015 to 2021

Table 2: Global Value (US$ Million),By Phase, 2022 to 2032

Table 3: Global Value (US$ Million), By Type, 2015 to 2021

Table 4: Global Value (US$ Million), By Type, 2022 to 2032

Table 5: Global Value (US$ Million), By Test Type, 2015 to 2021

Table 6: Global Value (US$ Million), By Test Type, 2022 to 2032

Table 7: Global Value (US$ Million), By Therapeutic Area, 2015 to 2021

Table 8: Global Value (US$ Million), By Therapeutic Area, 2022 to 2032

Table 9: Global Large Molecule Bioanalytical Testing Services Market, By Region, 2015 to 2021

Table 10: Global Large Molecule Bioanalytical Testing Services Market, By Region, 2022 to 2032

Table 11: North America Value (US$ Million),By Phase, 2015 to 2021

Table 12: North America Value (US$ Million),By Phase, 2022 to 2032

Table 13: North America Value (US$ Million), By Type, 2015 to 2021

Table 14: North America Value (US$ Million), By Type, 2022 to 2032

Table 15: North America Value (US$ Million), By Test Type, 2015 to 2021

Table 16: North America Value (US$ Million), By Test Type, 2022 to 2032

Table 17: North America Value (US$ Million), By Therapeutic Area, 2015 to 2021

Table 18: North America Value (US$ Million), By Therapeutic Area, 2022 to 2032

Table 19: North America Large Molecule Bioanalytical Testing Services Market, By Country, 2015 to 2021

Table 20: North America Large Molecule Bioanalytical Testing Services Market, By Country, 2022 to 2032

Table 21: Latin America Value (US$ Million),By Phase, 2015 to 2021

Table 22: Latin America Value (US$ Million),By Phase, 2022 to 2032

Table 23: Latin America Value (US$ Million), By Type, 2015 to 2021

Table 24: Latin America Value (US$ Million), By Type, 2022 to 2032

Table 25: Latin America Value (US$ Million), By Test Type, 2015 to 2021

Table 26: Latin America Value (US$ Million), By Test Type, 2022 to 2032

Table 27: Latin America Value (US$ Million), By Therapeutic Area, 2015 to 2021

Table 28: Latin America Value (US$ Million), By Therapeutic Area, 2022 to 2032

Table 29: Latin America Large Molecule Bioanalytical Testing Services Market, By Country, 2015 to 2021

Table 30: Latin America Large Molecule Bioanalytical Testing Services Market, By Country, 2022 to 2032

Table 31: Europe Value (US$ Million),By Phase, 2015 to 2021

Table 32: Europe Value (US$ Million),By Phase, 2022 to 2032

Table 33: Europe Value (US$ Million), By Type, 2015 to 2021

Table 34: Europe Value (US$ Million), By Type, 2022 to 2032

Table 35: Europe Value (US$ Million), By Test Type, 2015 to 2021

Table 36: Europe Value (US$ Million), By Test Type, 2022 to 2032

Table 37: Europe Value (US$ Million), By Therapeutic Area, 2015 to 2021

Table 38: Europe Value (US$ Million), By Therapeutic Area, 2022 to 2032

Table 39: Europe Large Molecule Bioanalytical Testing Services Market, By Country, 2015 to 2021

Table 40: Europe Large Molecule Bioanalytical Testing Services Market, By Country, 2022 to 2032

Table 41: Asia Pacific Value (US$ Million),By Phase, 2015 to 2021

Table 42: Asia Pacific Value (US$ Million),By Phase, 2022 to 2032

Table 43: Asia Pacific Value (US$ Million), By Type, 2015 to 2021

Table 44: Asia Pacific Value (US$ Million), By Type, 2022 to 2032

Table 45: Asia Pacific Value (US$ Million), By Test Type, 2015 to 2021

Table 46: Asia Pacific Value (US$ Million), By Test Type, 2022 to 2032

Table 47: Asia Pacific Value (US$ Million), By Therapeutic Area, 2015 to 2021

Table 48: Asia Pacific Value (US$ Million), By Therapeutic Area, 2022 to 2032

Table 49: Asia Pacific Large Molecule Bioanalytical Testing Services Market, By Country, 2015 to 2021

Table 50: Asia Pacific Large Molecule Bioanalytical Testing Services Market, By Country, 2022 to 2032

Table 51: MEA Value (US$ Million),By Phase, 2015 to 2021

Table 52: MEA Value (US$ Million),By Phase, 2022 to 2032

Table 53: MEA Value (US$ Million), By Type, 2015 to 2021

Table 54: MEA Value (US$ Million), By Type, 2022 to 2032

Table 55: MEA Value (US$ Million), By Test Type, 2015 to 2021

Table 56: MEA Value (US$ Million), By Test Type, 2022 to 2032

Table 57: MEA Value (US$ Million), By Therapeutic Area, 2015 to 2021

Table 58: MEA Value (US$ Million), By Therapeutic Area, 2022 to 2032

Table 59: MEA Large Molecule Bioanalytical Testing Services Market, By Country, 2015 to 2021

Table 60: MEA Large Molecule Bioanalytical Testing Services Market, By Country, 2022 to 2032

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 2: Global Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 to 2032), US$ Million

Figure 3: Global Share, By Phase, 2022 & 2032

Figure 4: Global Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 5: Global Attractiveness Index, By Phase - 2022 to 2032

Figure 6: Global Share, By Type, 2022 & 2032

Figure 7: Global Y-o-Y Growth Projections, By Type - 2022 to 2032

Figure 8: Global Attractiveness Index, By Type - 2022 to 2032

Figure 9: Global Share, By Therapeutic Area, 2022 & 2032

Figure 10: Global Y-o-Y Growth Projections, By Therapeutic Area - 2022 to 2032

Figure 11: Global Attractiveness Index, By Therapeutic Area - 2022 to 2032

Figure 12: Global Share, By Test Type, 2022 & 2032

Figure 13: Global Y-o-Y Growth Projections, By Test Type - 2022 to 2032

Figure 14: Global Attractiveness Index, By Test Type - 2022 to 2032

Figure 15: Global Share, By Region, 2022 & 2032

Figure 16: Global Y-o-Y Growth Projections, By Region - 2022 to 2032

Figure 17: Global Attractiveness Index, By Region - 2022 to 2032

Figure 18: North America Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 19: North America Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 to 2032), US$ Million

Figure 20: North America Share, By Phase, 2022 & 2032

Figure 21: North America Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 22: North America Attractiveness Index, By Phase - 2022 to 2032

Figure 23: North America Share, By Type, 2022 & 2032

Figure 24: North America Y-o-Y Growth Projections, By Type - 2022 to 2032

Figure 25: North America Attractiveness Index, By Type - 2022 to 2032

Figure 26: North America Share, By Therapeutic Area, 2022 & 2032

Figure 27: North America Y-o-Y Growth Projections, By Therapeutic Area - 2022 to 2032

Figure 28: North America Attractiveness Index, By Therapeutic Area - 2022 to 2032

Figure 29: North America Share, By Test Type, 2022 & 2032

Figure 30: North America Y-o-Y Growth Projections, By Test Type - 2022 to 2032

Figure 31: North America Attractiveness Index, By Test Type - 2022 to 2032

Figure 32: North America Share, By Country, 2022 & 2032

Figure 33: North America Market Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 34: North America Market Attractiveness Index, By Country - 2022 to 2032

Figure 35: Latin America Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 36: Latin America Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 to 2032), US$ Million

Figure 37: Latin America Share, By Phase, 2022 & 2032

Figure 38: Latin America Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 39: Latin America Attractiveness Index, By Phase - 2022 to 2032

Figure 40: Latin America Share, By Type, 2022 & 2032

Figure 41: Latin America Y-o-Y Growth Projections, By Type - 2022 to 2032

Figure 42: Latin America Attractiveness Index, By Type - 2022 to 2032

Figure 43: Latin America Share, By Therapeutic Area, 2022 & 2032

Figure 44: Latin America Y-o-Y Growth Projections, By Therapeutic Area - 2022 to 2032

Figure 45: Latin America Attractiveness Index, By Therapeutic Area - 2022 to 2032

Figure 46: Latin America Share, By Test Type, 2022 & 2032

Figure 47: Latin America Y-o-Y Growth Projections, By Test Type - 2022 to 2032

Figure 48: Latin America Attractiveness Index, By Test Type - 2022 to 2032

Figure 49: Latin America Share, By Country, 2022 & 2032

Figure 50: Latin America Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 51: Latin America Attractiveness Index, By Country - 2022 to 2032

Figure 52: Europe Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 53: Europe Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 to 2032), US$ Million

Figure 54: Europe Share, By Phase, 2022 & 2032

Figure 55: Europe Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 56: Europe Attractiveness Index, By Phase - 2022 to 2032

Figure 57: Europe Share, By Type, 2022 & 2032

Figure 58: Europe Y-o-Y Growth Projections, By Type - 2022 to 2032

Figure 59: Europe Attractiveness Index, By Type - 2022 to 2032

Figure 60: Europe Share, By Therapeutic Area, 2022 & 2032

Figure 61: Europe Y-o-Y Growth Projections, By Therapeutic Area - 2022 to 2032

Figure 62: Europe Attractiveness Index, By Therapeutic Area - 2022 to 2032

Figure 63: Europe Share, By Test Type, 2022 & 2032

Figure 64: Europe Y-o-Y Growth Projections, By Test Type - 2022 to 2032

Figure 65: Europe Attractiveness Index, By Test Type - 2022 to 2032

Figure 66: Europe Share, By Country, 2022 & 2032

Figure 67: Europe Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 68: Europe Attractiveness Index, By Country - 2022 to 2032

Figure 69: MEA Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 70: MEA Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 to 2032), US$ Million

Figure 71: MEA Share, By Phase, 2022 & 2032

Figure 72: MEA Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 73: MEA Attractiveness Index, By Phase - 2022 to 2032

Figure 74: MEA Share, By Type, 2022 & 2032

Figure 75: MEA Y-o-Y Growth Projections, By Type - 2022 to 2032

Figure 76: MEA Attractiveness Index, By Type - 2022 to 2032

Figure 77: MEA Share, By Therapeutic Area, 2022 & 2032

Figure 78: MEA Y-o-Y Growth Projections, By Therapeutic Area - 2022 to 2032

Figure 79: MEA Attractiveness Index, By Therapeutic Area - 2022 to 2032

Figure 80: MEA Share, By Test Type, 2022 & 2032

Figure 81: MEA Y-o-Y Growth Projections, By Test Type - 2022 to 2032

Figure 82: MEA Attractiveness Index, By Test Type - 2022 to 2032

Figure 83: MEA Share, By Country, 2022 & 2032

Figure 84: MEA Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 85: MEA Attractiveness Index, By Country - 2022 to 2032

Figure 86: Asia Pacific Value (US$ Million) and Year-on-Year Growth, 2015 to 2032

Figure 87: Asia Pacific Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 to 2032), US$ Million

Figure 88: Asia Pacific Share, By Phase, 2022 & 2032

Figure 89: Asia Pacific Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 90: Asia Pacific Attractiveness Index, By Phase - 2022 to 2032

Figure 91: Asia Pacific Share, By Type, 2022 & 2032

Figure 92: Asia Pacific Y-o-Y Growth Projections, By Type - 2022 to 2032

Figure 93: Asia Pacific Attractiveness Index, By Type - 2022 to 2032

Figure 94: Asia Pacific Share, By Therapeutic Area, 2022 & 2032

Figure 95: Asia Pacific Y-o-Y Growth Projections, By Therapeutic Area - 2022 to 2032

Figure 96: Asia Pacific Attractiveness Index, By Therapeutic Area - 2022 to 2032

Figure 97: Asia Pacific Share, By Test Type, 2022 & 2032

Figure 98: Asia Pacific Y-o-Y Growth Projections, By Test Type - 2022 to 2032

Figure 99: Asia Pacific Attractiveness Index, By Test Type - 2022 to 2032

Figure 100: Asia Pacific Share, By Country, 2022 & 2032

Figure 101: Asia Pacific Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 102: Asia Pacific Attractiveness Index, By Country - 2022 to 2032